In contrast, breast cancers may retain ligand dependence for longer, permitting the paradoxical acquisition of both elevated estrogen-mediated ER-FOXA1 activity and increased sensitivity to drugs that block this pathway. Here, FOXA1 is linked to breast carcinoma.